OSLO, NORWAY--(Marketwire - Mar 19, 2013) - Algeta ASA (
Algeta's Annual General Meeting will be held on 11 April 2013 at 16:00hours(CET) at the offices of Algeta ASA at Kjelsåsveien 172A, Oslo, Norway.
Please find attached the Notice of Algeta ASA's Annual General Meeting,proposedamended charter for the nomination committee, and attendance slip and proxyform. These are, together with the annual report, also available onwww.algeta.com in the Investor section.
Algeta is a company focused on developing novel targeted therapies forpatientswith cancer based on its alpha-pharmaceutical platform. The Company isheadquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC,based inCambridge, MA performing commercial marketing operations in the US. Algetaislisted on the Oslo Stock Exchange (ALGETA.OL). For more informationpleasevisit www.algeta.com.
Notice of Attendance of Annual General Meeting in Algeta ASA:http://hugin.info/134655/R/1686069/552595.pdf
Attendance and proxy form:http://hugin.info/134655/R/1686069/552597.pdf
Proposed amended charter for the Nomination Committee:http://hugin.info/134655/R/1686069/552596.pdf
This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE[HUG#1686069]
- Investment & Company Information
- Annual General Meeting
For further information, please contact:
Mike Booth / Renate Birkeli
Communications & Corporate Affairs
+47 23 00 67 32
Citigate Dewe Rogerson
+44 207 638 9571
Gambit Hill & Knowlton
+47 22 04 82 00
MacDougall Biomedical Communications
+1 781 235 3060
US investor enquiries:
The Trout Group
+1 646 378 2953